Immunotherapy toxicity survey

UCLH cancer academy has been funded to develop multidisciplinary education on check point inhibitors and immune related adverse events.  We are very keen that the materials we produced are helpful to the whole BOPA membership.  To understand where the gaps are we have developed a questionnaire (see link below).  It will take less than 10 minutes to complete and will be really helpful for us to understand where the gaps are at different hospitals.  Please could this be completed by June 2nd.  If you have any questions or would like to keep in touch with our work, then please email Elly on [email protected].

https://forms.office.com/e/rAAj4DzjNK

Latest News

By Joseph Williams on 8th June 2026

BOPA and Pharmaceutical Journal (PJ) Collaboration – Advanced therapy medicinal products: a tsunami in clinical medicine (By BOPA Member – Nisha Shaunak)

This article is brought to you as part of a collaboration with the Pharmaceutical Journal (PJ). The views expressed in this article are those of the author and are not…

Read article
By BOPA E&T Subcommittee on 4th June 2026

SAVE THE DATE: BOPA Introduction to Cancer Course, London, September 2026 – Registration opens soon!

The popular Introduction to Cancer Course is coming to London in September 2026 The BOPA Introduction to Cancer Course 2026 WHEN: Thursday 17th & Friday 18th September 2026 WHERE: University College Hospital,…

Read article
By Macmillan Cancer Support on 4th June 2026

Cancer Information Development team at Macmillan Cancer Support

Dear BOPA members, The Cancer Information Development team at Macmillan Cancer Support would like to make you aware of a couple of new cancer treatment information pages on our website:…

Read article
By Clayton Wong on 1st June 2026

Launch of Bespoke Health Technology Assessment Course

Bespoke CPD Course on Health Technology Assessment (HTA)    We are delighted to see the launch of the BOPA Health Technology Assessment (HTA) course, which represents an important step forward in supporting the cancer pharmacy workforce…

Read article